Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|February 1, 2018

Ralf Otto Named COO at Rentschler Biopharma

Biopharm industry veteran Ralf Otto named to lead development and manufacturing at Rentschler Biopharma.

Rentschler Biopharma, a contract development and manufacturing organization for biopharmaceuticals, appointed Ralf Otto as chief operating officer (COO), effective Feb. 1, 2018, succeeding Thomas Siklosi, who will move to Dr. Rentschler Holding GmbH & Co. KG, according to a Jan. 31, 2018 press statement.

Otto-who will be responsible for development, manufacturing, and quality management-has more than 20 years at senior positions in industry and management consulting and has overseen all stages of the biopharmaceutical value chain.

Most recently, he was a Partner at McKinsey & Company.  Previously, he held executive positions in cell biology and biopharmaceutical manufacturing at Boehringer Ingelheim and as vice-president Biopharma Operations, Otto headed the Boehringer site in Fremont, CA.

Source:  Rentschler Biopharma SE

 

 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.